Vimarsana
Biggest News Aggregation in the World

Page 3 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

EQS-News: Immunic to Participate in Scientific Conferences in October - Vimarsana News

EQS-News: Immunic to Participate in Scientific Conferences in October

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific Conferences in October 04.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific Conferences in October NEW YORK, October 4, 2023 – I...

EQS-News: Immunic to Participate in Industry and Investor Conferences in September - Vimarsana News

EQS-News: Immunic to Participate in Industry and Investor Conferences in September

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Industry and Investor Conferences in September 06.09.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Industry and Investor Conferences in September NEW...

Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky - Vimarsana News

Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Source: yahoo.com
Immunic (NASDAQ:IMUX) Now Covered by Analysts at StockNews.com - Vimarsana News

Immunic (NASDAQ:IMUX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the stock. Separately, Wedbush reaffirmed an outperform rating and set a $5.00 price target on shares of Immunic in a research report on Friday, August 4th. View Our […]

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis - Vimarsana News

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...